Modelling Considerations for Evaluating the Cost-Effectiveness of Biologics

Chris Knight, MSc
Executive Director, Health Economics

Transcript:

In this study, we identified challenges in designing conceptual models for biologic therapies in eosinophilic-associated diseases.

We performed a targeted search of the Embase database and health technology assessment agency websites to identify examples of cost-effectiveness modeling. The model structures often included health states defined by levels of disease and treatment response. However, vague definitions of disease control and a lack of consensus on treatment response posed a challenge in evaluating comparative treatment efficacy. Other challenges included understanding long-term treatment efficacy, identifying appropriate treatment stopping rules, finding publications reporting stratified cost and utility estimates, and difficulty quantifying the costs and disutility of long-term steroids use.

We recommend early engagement with clinical experts and payers for reaching a consensus on positioning biologics and creating clear definitions of disease control and treatment response. Further research on resource use and utility associated with different levels of disease activity is needed.

Jia X, Knight C. Modelling considerations for evaluating the cost-effectiveness of biologics in eosinophilic-associated diseases. Poster presented at the ISPOR Europe 2023; November 15, 2023. Copenhagen, Denmark.